Literature DB >> 26045310

Breast Cancer Staging: To Which Women Should 18F-FDG PET/CT Be Offered?

David Groheux1, Elif Hindié1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26045310     DOI： 10.2967/jnumed.115.160945

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  4 in total

Review 1.  The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer.

Authors:  Koosha Paydary; Siavash Mehdizadeh Seraj; Mahdi Zirakchian Zadeh; Sahra Emamzadehfard; Sara Pourhassan Shamchi; Saeid Gholami; Thomas J Werner; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

2.  18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer.

Authors:  Gary A Ulaner; Raychel Castillo; Jonathan Wills; Mithat Gönen; Debra A Goldman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-29       Impact factor: 9.236

3.  (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.

Authors:  Gary A Ulaner; Raychel Castillo; Debra A Goldman; Jonathan Wills; Christopher C Riedl; Katja Pinker-Domenig; Maxine S Jochelson; Mithat Gönen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-30       Impact factor: 9.236

4.  Hormonal Receptor Immunochemistry Heterogeneity and 18F-FDG Metabolic Heterogeneity: Preliminary Results of Their Relationship and Prognostic Value in Luminal Non-Metastatic Breast Cancers.

Authors:  Nicolas Aide; Nicolas Elie; Cécile Blanc-Fournier; Christelle Levy; Thibault Salomon; Charline Lasnon
Journal:  Front Oncol       Date:  2021-01-12       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.